• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy.

作者信息

Teisseyre Maxime, Brglez Vesna, Cremoni Marion, Fernandez Céline, Graça Daisy, Boyer-Suavet Sonia, Benzaken Sylvia, Esnault Vincent L M, Seitz-Polski Barbara

机构信息

Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, CHU de Nice, Université Côte d'Azur, Nice, France.

Service de Néphrologie-Dialyse-Transplantation, CHU de Nice, Université Côte d'Azur, Nice, France.

出版信息

Clin J Am Soc Nephrol. 2023 Jun 1;18(6):785-787. doi: 10.2215/CJN.0000000000000152. Epub 2023 Apr 17.

DOI:10.2215/CJN.0000000000000152
PMID:36942995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10278856/
Abstract
摘要

相似文献

1
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy.膜性肾病中抗利妥昔单抗抗体产生的相关危险因素
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):785-787. doi: 10.2215/CJN.0000000000000152. Epub 2023 Apr 17.
2
Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.抗磷脂酶A2受体抗体与膜性肾病的免疫抑制：抗磷脂酶A2受体自身抗体致病性的更多证据
J Am Soc Nephrol. 2015 Oct;26(10):2308-11. doi: 10.1681/ASN.2015020181. Epub 2015 Mar 24.
3
[Membranous nephropathy: New insights in therapeutic approach].[膜性肾病：治疗方法的新见解]
Nephrol Ther. 2017 Apr;13 Suppl 1:S83-S87. doi: 10.1016/j.nephro.2017.02.002.
4
Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.利妥昔单抗对伴有抗磷脂酶A2受体抗体滴度持续升高的膜性肾病进行再治疗。
Kidney Int. 2019 Jan;95(1):233-234. doi: 10.1016/j.kint.2018.08.045.
5
Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.儿童特发性膜性肾病用利妥昔单抗治疗：两例报告。
Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15.
6
Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.接触蛋白-1相关性膜性肾病：利妥昔单抗治疗实现完全免疫缓解和临床缓解
Kidney Int. 2021 Dec;100(6):1342-1344. doi: 10.1016/j.kint.2021.08.029.
7
Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.评价利妥昔单抗治疗膜性肾病的疗效：11 项研究的系统评价和荟萃分析。
Nephrol Ther. 2022 Apr;18(2):104-112. doi: 10.1016/j.nephro.2021.10.002. Epub 2022 Jan 21.
8
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.抗磷脂酶A2受体抗体滴度可预测利妥昔单抗治疗后膜性肾病的疗效。
J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.
9
Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.在膜性肾病临床表现出现之前，血清抗磷脂酶A2受体（PLA2R）抗体可能已经存在。
Kidney Int. 2016 Jun;89(6):1399. doi: 10.1016/j.kint.2015.11.032.
10
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.磷脂酶A2受体（PLA2R）抗体相关膜性肾病的免疫缓解：环磷酰胺与利妥昔单抗对比
Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019.

引用本文的文献

1
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy.原发性膜性肾病患者中抗利妥昔单抗抗体的发生情况及临床结局
Kidney Int Rep. 2025 May 6;10(8):2621-2629. doi: 10.1016/j.ekir.2025.04.059. eCollection 2025 Aug.
2
Anti-Rituximab Antibodies in Primary Membranous Nephropathy: Time for Routine Monitoring in Clinical Practice?原发性膜性肾病中的抗利妥昔单抗抗体：临床实践中进行常规监测的时候到了吗？
Kidney Int Rep. 2025 Jun 21;10(8):2545-2547. doi: 10.1016/j.ekir.2025.06.033. eCollection 2025 Aug.
3
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.奥妥珠单抗和奥法木单抗在治疗伴有抗利妥昔单抗抗体的膜性肾病患者方面比利妥昔单抗更有效。
Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar.
4
Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial.基于人工智能的膜性肾病利妥昔单抗个体化治疗方案（iRITUX）：一项多中心随机对照试验方案
BMJ Open. 2025 Apr 2;15(4):e093920. doi: 10.1136/bmjopen-2024-093920.
5
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence.利用人工智能优化成人抗磷脂酶A2受体1相关膜性肾病患者的利妥昔单抗治疗
Kidney Int Rep. 2023 Nov 3;9(1):134-144. doi: 10.1016/j.ekir.2023.10.023. eCollection 2024 Jan.
6
Targeting therapy in pemphigus: Where are we now and where are we going?天疱疮的靶向治疗：我们目前的状况及未来走向？
Heliyon. 2023 May 25;9(6):e16679. doi: 10.1016/j.heliyon.2023.e16679. eCollection 2023 Jun.